Two biotech firms and a radiochemistry company will develop next-generation targeted alpha-therapies to treat various forms of cancer.

Sanofi has announced that the US Food and Drug Administration (FDA) has accepted its supplemental biologics licence application (sBLA) for priority review for the treatment of bullous pemphigoid (BP). The sBLA is for Dupixent (dupilumab), which has already received regulatory approvals in more than 60 countries for certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urtica

Leading provider of digital identification and traceability software solutions, Systech, has announced the launch of UniSecure artAI.

Korean company Rznomics has announced that its gene therapy-based cancer drug candidate has been granted Fast Track designation (FTD) by the US Food and Drug Administration (FDA). It is indicated for use in hepatocellular carcinoma (HCC).

Biotechnology company Eikon Therapeutics has announced the initial closing of its Series D funding round, securing $350.7m to support its current therapeutic pipeline and contribute to its goal of integrating advanced engineering with molecular and cell biology.

The GSK-Oxford Cancer Immuno-Prevention Programme was announced at the end of January and will focus on researching the prevention of cancer through vaccination. The programme is an additional development to the existing relationship between Oxford University and GSK, including the GSK-Oxford Institute of Molecular and Computational Medicine in Oxford, UK.

Upperton Pharma Solutions, a contract and development manufacturing organisation (CDMO) based in the north of England, UK, has announced the expansion of its 50,000ft22 site Trent Gateway with the newly-completed £7m sterile manufacturing facility.

Takeda,aglobal biopharmaceutical company, is due to launch a project, INTERCEPT, which will use biomarkers to prevent symptomatic onset of Crohns Disease before the disease begins to affect patients, later in February. The trial is a first in Europe.

Aravax, a biotechnology company specialising in next-generation immunotherapies, has launched a UK subsidiary at the Oxford Science Park.

UK-based SPT Labtech and Chinese CRO ICE Bioscience have announced the development of a joint laboratory to be built in China. The collaboration seeks to create a state-ofthe-art lab for intelligent drug screening and pharma automation.

Developer and supplier of critical raw materials Biosynth, has opened the doors to its Biosynth Biological Technology site in Suzhou, China.

Recipharm and Exela have announced that they have entered into an exclusive strategic alliance. The alliance between the two contract development and manufacturing organisations (CDMOs) aims to enhance sterile manufacturing capabilities in the US. As part of the alliance, Recipharm will be able to take advantage of Exela’s state-of-the-art manufacturing plant in Lenoir, NC, US.